Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2025-07-22 Capital/Financing Update
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 4 to a Form S-1 Registration Statement filed with the SEC, dated July 22, 2025. It is a registration statement under the Securities Act of 1933 for AIM ImmunoTech Inc. The text includes detailed information about the securities being offered, the offering terms, the company's compliance with listing standards, and the plan of distribution. This is a typical filing for a public offering of securities, specifically a registration statement for an equity offering. The document is not an annual or quarterly report, audit report, earnings release, or any other type of financial report. It is a capital raising filing related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear identification of the form and content.
2025-07-22 English
Director's Dealing 2025
Director's Dealing
2025-07-21 English
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by AIM ImmunoTech Inc. on July 15, 2025. Form S-8 is used to register securities to be offered under employee benefit plans, such as equity incentive plans. The document registers additional shares under the company's Amended and Restated 2018 Equity Incentive Plan. It includes legal and procedural information, incorporation by reference of prior filings, and signatures of company officers. There are no financial statements or earnings data presented, nor is this an announcement of a report or voting results. This is a capital/financing related filing concerning equity incentive plan shares registration, which fits the Capital/Financing Update category (CAP).
2025-07-15 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC regarding an Amendment No. 3 to a Registration Statement on Form S-1. It is a correspondence filing related to a registration statement, not a financial report or announcement of results. The document is short (1124 characters) and is a formal communication about a regulatory filing. It does not contain financial data, management discussion, or report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications and filings that do not fit other specific categories.
2025-07-15 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 3 to a Form S-1 Registration Statement filed with the SEC, dated July 15, 2025. It includes detailed information about a securities offering, including the number and type of securities offered, pricing, placement agent details, and compliance with exchange listing rules. The Form S-1 is a registration statement used for initial public offerings or other securities offerings to register securities with the SEC. This document is not a financial report, earnings release, or management discussion, but rather a capital raising filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full offering details, not just an announcement or summary, confirming it is a primary filing for capital raising.
2025-07-15 English
Regulatory Filings 2025
Regulatory Filings
2025-07-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.